Updated just now · Live
Stock analysis, price data, and AI-powered insights for Amgen (AMGN).
Amgen operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for AMGN.
How to read insider trading filings
Johnson & Johnson
UnitedHealth Group Incorporated
AbbVie Inc.
Merck & Co., Inc.
Eli Lilly and Company
Thermo Fisher Scientific Inc.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). AMGN Stock Intelligence Report. [stoxpulse.com/stocks/amgn]
Disclaimer: The information on this page about Amgen (AMGN) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Amgen.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No earnings data available.
Earnings Scheduled For April 30, 2026
9h ago
Elizabeth Warren Calls Trump's '600%' Drug Price C...
11h ago
StoxPulse AI results for AMGN: Pulse Score 52.5/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$182.42B
P/E Ratio
—
EPS
$5.93
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Sector
Healthcare
Industry
Biotechnology
Earnings Scheduled For April 30, 2026
Elizabeth Warren Calls Trump's '600%' Drug Price Claim Mathematically Impossible: 'His Promise Is As Empty As…'
Apple earnings, March PCE, Q1 GDP, mortgage rates: What to Watch
Earnings To Watch: Amgen (AMGN) Reports Q1 Results Tomorrow
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength
Update: Amgen's Tavneos Proposed to be Withdrawn by US FDA's Center for Drug Evaluation and Research
Biocon Launches Denosumab Biosimilars